Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Decline in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 175,600 shares, a decrease of 72.2% from the August 31st total of 632,400 shares. Approximately 4.3% of the company’s stock are short sold. Based on an average daily volume of 4,500,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new stake in Virax Biolabs Group Limited (NASDAQ:VRAX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned 7.87% of Virax Biolabs Group as of its most recent filing with the SEC. 8.61% of the stock is currently owned by hedge funds and other institutional investors.

Virax Biolabs Group Price Performance

Shares of VRAX stock remained flat at $1.93 on Friday. The stock had a trading volume of 26,766 shares, compared to its average volume of 2,082,049. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00. The firm’s 50 day moving average price is $2.66 and its 200 day moving average price is $1.57.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.